TobaccoAsia/ InterTabac Podcast #54

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Add to basket failed.

Please try again later

Add to wishlist failed.

Please try again later

Remove from wishlist failed.

Please try again later

Adding to library failed

Please try again

Follow podcast failed

Unfollow podcast failed

TobaccoAsia/ InterTabac Podcast #54

Listen for free

View show details

Thomas Schmid interviews Mark McQuillan, the managing director of Nicobrand, one of the world's largest pharmaceutical-grade nicotine suppliers. McQuillan explains what truly qualifies nicotine as "pharmaceutical grade." For instance, beyond basic monographs, it requires regulatory audits, drug master files, and strict impurity controls. McQuillan argues that all next-generation products like pouches and e-liquids should use pharma-grade nicotine to ensure consumer safety. The global nicotine market is roughly 1,000–1,500 metric tons annually, with nicotine pouches growing fastest. McQuillan also stresses the importance of supply chain transparency and correcting the widespread misconception that nicotine itself causes cancer.

No reviews yet